How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? a Bayesian design

Intensive Care Medicine

Volumn 34, Issue 10, 2008, Pages 1804-1811

  Kalil, Andre C ^a,c   Sun, Junfeng ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Bayesian methodology; Drotrecogin alfa activated; Severe sepsis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; DROTRECOGIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; BAYES THEOREM; CAUSE OF DEATH; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; RANDOMIZED CONTROLLED TRIAL; SEPSIS;

ANTI-INFECTIVE AGENTS; BAYES THEOREM; HUMANS; MULTIPLE ORGAN FAILURE; ODDS RATIO; PROTEIN C; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; SEPSIS; TREATMENT OUTCOME;

EID: 52949093524     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-008-1159-8     Document Type: Article

References (44)

1. KJ Deans PC Minneci X Cui SM Banks C Natanson PQ Eichacker 2005 Mechanical ventilation in ARDS: one size does not fit all Crit Care Med 33 1141 1143
2. JO Friedrich NK Adhikari MO Meade 2006 Drotrecogin alfa (activated): down and not out, but not really in either Crit Care 10 420
3. CJ Wiedermann 2006 When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated) Intens Care Med 32 604
4. AF Mackenzie 2005 Activated protein C: do more survive? Intens Care Med 31 1624 1626
5. PQ Eichacker RL Danner AF Suffredini X Cui C Natanson 2005 Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial Crit Care Med 33 2426 2428
6. MJ Schultz EK Wolthuis HS Moeniralam M Levi 2005 Struggle for implementation of new strategies in intensive care medicine: anticoagulation, insulin, and lower tidal volumes J Crit Care 20 199 204
7. HS Warren AF Suffredini PQ Eichacker RS Munford 2002 Risks and benefits of activated protein C treatment for severe sepsis N Engl J Med 347 1027 1030
8. GR Bernard JL Vincent PF Laterre SP LaRosa JF Dhainaut A Lopez-Rodriguez JS Steingrub GE Garber JD Helterbrand EW Ely CJ Fisher Jr 2001 Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 699 709
9. DJ Cook JA Russell 2001 Recombinant human activated protein C reduced all-cause mortality in patients with severe sepsis ACP J Club 135 81
10. J Barkun NV Christou 2003 Canadian Association of General Surgeons Evidence Based Reviews in Surgery. 8. Efficacy and safety of recombinant human activated protein C for severe sepsis Can J Surg 46 468 470
11. MA Matthay 2001 Severe sepsis-a new treatment with both anticoagulant and antiinflammatory properties N Engl J Med 344 759 762
12. BL Davidson WH Geerts AW Lensing 2002 Low-dose heparin for severe sepsis N Engl J Med 347 1036 1037
13. E Abraham PF Laterre R Garg H Levy D Talwar BL Trzaskoma B Francois JS Guy M Bruckmann A Rea-Neto R Rossaint D Perrotin A Sablotzki N Arkins BG Utterback WL Macias 2005 Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death N Engl J Med 353 1332 1341
14. J Carlet 2006 Drotrecogin-alpha (activated) did not reduce death and increased bleeding in patients with severe sepsis and low risk for death ACP J Club 144 43
15. S Gupta EB Milbrandt L Chelluri 2006 Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death Crit Care 10 316
16. JE Parrillo 2005 Severe sepsis and therapy with activated protein C N Engl J Med 353 1398 1400
17. SP LaRosa 2006 Drotrecogin alfa (activated) in severe sepsis N Engl J Med 354 94 96 author reply 94-96
18. JO Friedrich 2006 Drotrecogin alfa (activated) in severe sepsis N Engl J Med 354 94 96 author reply 94-96
19. JK Baillie G Murray 2006 Drotrecogin alfa (activated) in severe sepsis N Engl J Med 354 94 96 author reply 94-96
20. PC Minneci KJ Deans X Cui SM Banks C Natanson PQ Eichacker 2006 Antithrombotic therapies for sepsis: a need for more studies Crit Care Med 34 538 541
21. E Abraham K Reinhart S Opal I Demeyer C Doig AL Rodriguez R Beale P Svoboda PF Laterre S Simon B Light H Spapen J Stone A Seibert C Peckelsen C De Deyne R Postier V Pettila A Artigas SR Percell V Shu C Zwingelstein J Tobias L Poole JC Stolzenbach AA Creasey 2003 Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial JAMA 290 238 247
22. BL Warren A Eid P Singer SS Pillay P Carl I Novak P Chalupa A Atherstone I Penzes A Kubler S Knaub HO Keinecke H Heinrichs F Schindel M Juers RC Bone SM Opal 2001 Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial JAMA 286 1869 1878
23. PR Burton LC Gurrin MJ Campbell 1998 Clinical significance not statistical significance: a simple Bayesian alternative to p values J Epidemiol Community Health 52 318 323
24. JA Sterne G Davey Smith 2001 Sifting the evidence-what's wrong with significance tests? BMJ 322 226 231
25. CJ Gill L Sabin CH Schmid 2005 Why clinicians are natural bayesians BMJ 330 1080 1083
26. GA Diamond S Kaul 2004 Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials J Am Coll Cardiol 43 1929 1939
27. DA Berry 2006 Bayesian clinical trials Nat Rev Drug Discov 5 27 36
28. FE Harrell Jr YC Shih 2001 Using full probability models to compute probabilities of actual interest to decision makers Int J Technol Assess Health Care 17 17 26
29. DJ Spiegelhalter JP Myles DR Jones KR Abrams 2000 Bayesian methods in health technology assessment: a review Health Technol Assess 4 1 130
30. SN Goodman 2005 Introduction to Bayesian methods. I: measuring the strength of evidence Clin Trials 2 282 290 discussion 301-284, 364-278
31. WS Browner TB Newman 1987 Are all significant P values created equal? The analogy between diagnostic tests and clinical research JAMA 257 2459 2463
32. F Davidoff 1999 Standing statistics right side up Ann Intern Med 130 1019 1021
33. (2001) FDA label: Xigris Drotrecogin alfa (activated). In:FDA
34. GR Bernard EW Ely TJ Wright J Fraiz JE Stasek Jr JA Russell I Mayers BA Rosenfeld PE Morris SB Yan JD Helterbrand 2001 Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis Crit Care Med 29 2051 2059
35. P Barton AC Kalil S Nadel B Goldstein R Okhuysen-Cawley RJ Brilli JS Takano LD Martin P Quint TS Yeh HJ Dalton MR Gessouron KE Brown H Betts M Levin WL Macias DS Small VL Wyss BM Bates BG Utterback BP Giroir 2004 Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis Pediatrics 113 7 17
36. RA Balk C Bedrosian 1995 Prospective, double-blind, placebo-controlled, trial of ATIII substitution in sepsis Intens Care Med 21 S17
37. HP Schuster B Eisele M Lamy LG Thijs 1997 S-ATIII study: antithrombin III in patients with sepis Intens Care Med S23 S76
38. F Fourrier C Chopin JJ Huart I Runge C Caron J Goudemand 1993 Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation Chest 104 882 888
39. D Inthorn JN Hoffmann WH Hartl D Muhlbayer M Jochum 1997 Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction Shock 8 328 334
40. B Eisele M Lamy LG Thijs HO Keinecke HP Schuster FR Matthias F Fourrier H Heinrichs U Delvos 1998 Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis Intens Care Med 24 663 672
41. E Abraham K Reinhart P Svoboda A Seibert D Olthoff A Dal Nogare R Postier G Hempelmann T Butler E Martin C Zwingelstein S Percell V Shu A Leighton AA Creasey 2001 Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study Crit Care Med 29 2081 2089
42. WL Macias B Vallet GR Bernard JL Vincent PF Laterre DR Nelson PA Derchak JF Dhainaut 2004 Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis Crit Care Med 32 2385 2391
43. Spiegelhalter DJ, Abrams KR, Myles JP (2004) Bayesian approaches to clinical trials and health care evaluation. Wiley, Chichester, Hoboken
44. Rosner B (2006) Fundamentals of biostatistics. Thomson-Brooks/Cole, Belmont